Management of Deep Vein Thrombosis

Rationale for Avoiding SCDs in Active DVT

The American Society of Hematology (ASH) 2020 guidelines do not recommend mechanical compression for patients with established DVT, focusing instead on appropriate anticoagulation as the primary treatment 1
A common clinical pitfall is continuing mechanical compression in patients who develop DVT while on prophylactic SCDs - these devices should be discontinued once DVT is diagnosed 1

Anticoagulation is the mainstay of treatment for DVT to prevent thrombus propagation and pulmonary embolism 2
Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for initial treatment due to their better safety profile and comparable efficacy 2
For most patients with uncomplicated DVT, home treatment is suggested over hospital treatment, provided the patient has adequate support at home and no high bleeding risk 2

The ASH 2020 guidelines suggest against the routine use of compression stockings for prevention of post-thrombotic syndrome in patients with DVT (conditional recommendation based on very low certainty evidence) 3
Compression stockings may help reduce edema and pain associated with DVT in selected patients, but should only be considered after initial anticoagulation therapy 3, 1

For extensive proximal DVT involving the superficial femoral and popliteal veins with lack of compression and flow, thrombolysis may be considered rather than compression devices 2
Thrombolytic therapy should be especially considered in younger patients at low risk for bleeding with symptomatic proximal DVT 2
In patients with limb-threatening DVT (phlegmasia cerulea dolens), catheter-directed thrombolysis should be considered as an urgent intervention rather than compression therapy 4, 2

For first episode DVT secondary to transient risk factors, 3-6 months of anticoagulation is recommended 2
For recurrent or unprovoked iliofemoral DVT, patients should have at least 6 months of anticoagulation and be considered for indefinite anticoagulation with periodic reassessment 5, 2
Cancer patients with iliofemoral DVT should receive LMWH monotherapy for at least 3 to 6 months, or as long as the cancer or its treatment is ongoing 5, 2

For patients with iliofemoral DVT, the American Heart Association suggests daily use of 30-40 mm Hg knee-high graduated elastic compression stockings for at least 2 years after diagnosis, but only after initial anticoagulation therapy 5
In patients with severe edema resulting from DVT, intermittent sequential pneumatic compression followed by daily use of 30-40 mm Hg knee-high graduated elastic compression stockings may be considered, but only after adequate treatment of the acute DVT 5